Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Clinical Research and Equipment Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Fri, 17 Jul 2026	HK$346.9b	HK$48.6b	HK$1.2b	35.7x	289x	7.1x
Sun, 14 Jun 2026	HK$282.4b	HK$48.6b	HK$1.2b	28.9x	234x	5.8x
Tue, 12 May 2026	HK$333.6b	HK$48.4b	HK$1.2b	30x	286x	6.9x
Thu, 09 Apr 2026	HK$343.6b	HK$48.2b	HK$1.1b	33.1x	304.4x	7.1x
Sat, 07 Mar 2026	HK$342.7b	HK$43.6b	HK$6.1b	40.7x	56.3x	7.9x
Mon, 02 Feb 2026	HK$366.8b	HK$43.3b	HK$6.0b	42.7x	60.7x	8.5x
Wed, 31 Dec 2025	HK$295.5b	HK$42.5b	HK$6.3b	43.7x	46.7x	7x
Fri, 28 Nov 2025	HK$304.4b	HK$42.0b	HK$6.2b	44.9x	48.8x	7.2x
Sun, 26 Oct 2025	HK$336.8b	HK$41.8b	HK$6.2b	47.9x	54.3x	8.1x
Tue, 23 Sep 2025	HK$362.0b	HK$41.9b	HK$6.2b	50.4x	58.3x	8.6x
Thu, 21 Aug 2025	HK$287.9b	HK$41.5b	HK$4.5b	57.7x	64.2x	6.9x
Sat, 19 Jul 2025	HK$254.8b	HK$37.2b	HK$2.7b	50.9x	93x	6.8x
Mon, 16 Jun 2025	HK$236.4b	HK$36.2b	HK$2.6b	31.1x	90.6x	6.5x
Wed, 14 May 2025	HK$187.5b	HK$35.9b	HK$2.6b	25.9x	72.6x	5.2x
Fri, 11 Apr 2025	HK$163.6b	HK$35.2b	HK$2.5b	24.4x	65x	4.6x
Sun, 09 Mar 2025	HK$200.0b	HK$35.9b	-HK$1,056,224,592.40	44.4x	-189.3x	5.6x
Tue, 04 Feb 2025	HK$156.2b	HK$36.0b	-HK$1,059,833,639.34	52.6x	-147.4x	4.3x
Thu, 02 Jan 2025	HK$158.6b	HK$35.7b	-HK$1,058,290,871.23	58x	-149.9x	4.4x
Sat, 30 Nov 2024	HK$136.7b	HK$35.9b	-HK$1,058,204,562.01	51.7x	-129.1x	3.8x
Mon, 28 Oct 2024	HK$163.9b	HK$35.7b	-HK$659,995,106.50	31.6x	-248.4x	4.6x
Wed, 25 Sep 2024	HK$143.2b	HK$36.1b	-HK$653,046,298.07	26.8x	-219.2x	4x
Fri, 23 Aug 2024	HK$94.3b	HK$35.9b	HK$2.0b	16.6x	47.1x	2.6x
Sun, 21 Jul 2024	HK$93.2b	HK$33.4b	HK$3.1b	18.4x	30.3x	2.8x
Tue, 18 Jun 2024	HK$92.3b	HK$33.5b	HK$3.1b	23.2x	30x	2.8x
Thu, 16 May 2024	HK$111.2b	HK$33.6b	HK$3.1b	30.7x	35.9x	3.3x
Sat, 13 Apr 2024	HK$111.9b	HK$33.6b	HK$3.1b	32.2x	36.1x	3.3x
Mon, 11 Mar 2024	HK$133.1b	HK$32.3b	HK$3.0b	59.6x	44.7x	4.1x
Wed, 07 Feb 2024	HK$132.2b	HK$32.6b	HK$3.0b	52x	43.7x	4.1x
Fri, 05 Jan 2024	HK$203.8b	HK$32.4b	HK$3.0b	90.7x	68x	6.3x
Sun, 03 Dec 2023	HK$276.7b	HK$32.4b	HK$3.0b	94.2x	92x	8.5x
Tue, 31 Oct 2023	HK$269.7b	HK$30.1b	HK$2.7b	48.4x	101.3x	9x
Thu, 28 Sep 2023	HK$241.3b	HK$30.1b	HK$2.7b	42.6x	90.5x	8x
Sat, 26 Aug 2023	HK$235.8b	HK$30.3b	HK$2.7b	23.5x	85.9x	7.8x
Mon, 24 Jul 2023	HK$221.3b	HK$28.5b	HK$2.7b	23.4x	81x	7.8x

Current Industry PE

Investors are optimistic on the Hong Kong Life Sciences Tools and Services industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 289x which is higher than its 3-year average PE of 28.9x.

The 3-year average PS ratio of 6.0x is lower than the industry's current PS ratio of 7.1x.

Past Earnings Growth

The earnings for companies in the Life Sciences Tools and Services industry have declined 24% per year over the last three years.
Meanwhile revenues for these companies have grown 19% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does Hong Kong Clinical Research and Equipment compare with similar industries?


HK Market	2.18%
Healthcare	6.38%
Life Sciences	5.62%
Clinical Research and Equipment	5.62%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

	Company	Last Price	7D	1Y	Valuation
	3696 InSilico Medicine Cayman TopCo	HK$43.20	0.9% +HK$217.5m	n/a	PS56.1x

Company

Last Price

Valuation

3696 InSilico Medicine Cayman TopCo

HK$43.20

0.9%
+HK$217.5m

n/a

PS56.1x

Zhejiang Taimei Medical Technology Co., Ltd. Announces Board and Committee Appointments, Effective June 23, 2026

Zhejiang Taimei Medical Technology Co., Ltd. at AGM on June 23, 2026 approved To elect Ms. WAN Yunyun as an executive Director. To elect Dr. GONG Yan as an independent non-executive Director. The directors are appointed for the third session of the Board of the Company. The term of office of the third session of the Board of the Company shall be three years, commencing from the date of approval at the AGM, and shall be eligible for re-election upon expiry of the term. The Company announced that, at the first meeting of the third session of the Board held immediately after the AGM, the Board passed the resolution on, among other things, the appointment of the following members of Board committees for a term of three years effective from June 23, 2026, and ending on the date of expiry of the third session of the Board. The details are as follows: Audit Committee; Mr. FUNG Che Wai Anthony(Chairman) Dr. JIANG Xiao Dr. GONG Yan Remuneration and Appraisal Committee Dr. GONG Yan (Chairman) Dr. ZHAO Lu Mr. FUNG Che Wai Anthony Nomination Committee Dr. ZHAO Lu (Chairman) Ms. NI XiaomeiDr. JIANG Xiao Mr. FUNG Che Wai Anthony Dr. GONG Yan. The Company announced that, at the first meeting of the third session of the Board held mmediately after the AGM, Dr. ZHAO Lu was appointed as the chairman of the third session of the Board for a term of three years effective from June 23, 2026, and ending on the date of expiry of the third session of the Board.

Hong Kong (HSI) Clinical Research and Equipment Industry Analysis

Industry Valuation and Performance

Industry Comparison

Top Stock Gainers and Losers

Latest News

Insilico Medicine Unveils $2.5b AI Drug Discovery Alliance With Bora Pharmaceuticals

WuXi XDC Cayman Inc. to Report First Half, 2026 Results on Aug 24, 2026

WuXi Biologics MFG8 Facility Cleared by FDA for US Commercial Production

New minor risk - Share price stability

New minor risk - Share price stability

Zhejiang Taimei Medical Technology Co., Ltd. Announces Board and Committee Appointments, Effective June 23, 2026

XtalPi Holdings (SEHK:2228) Stock Looks Hard To Justify After New R And D Alliance

Investor sentiment improves as stock rises 17%

Full year 2025 earnings released: EPS: CN¥0.066 (vs CN¥0.031 in FY 2024)